@Biostock The Dep Docetaxal Ph1 trial commenced in January 2014, 8.5 years ago and commenced the Ph 2 in September 2017 so it took almost 4 years to recruit 30 patients and run the trial, all in Australia. The alarm bells should have started ringing then however when they decided to shift the Ph 2 to the UK in order to expedite recruitment it appeared on the surface to be a smart move. At the time it was announced that because of the shift in trial site the trial would run for 2years.
That was 5 years ago.
8.5 years and Ph 2 is still running with no endpoint in sight.
I no longer believe
any of the statements coming from our overpaid CEO who perhaps would have been better suited in life writing fiction novels.
